Cite

    Garland, R. et al. (n.d.). 6 Pre-clinical pharmacodynamic biomarker assays of immune modulation can translate to inform exploratory endpoints of target engagement in first-in-human clinical trial stages of drug discovery. Journal for immunotherapy of cancer. p. A6. [Online].